MY121054A - Calcilytic compounds as calcium receptor antagonists. - Google Patents
Calcilytic compounds as calcium receptor antagonists.Info
- Publication number
- MY121054A MY121054A MYPI99001327A MYPI9901327A MY121054A MY 121054 A MY121054 A MY 121054A MY PI99001327 A MYPI99001327 A MY PI99001327A MY PI9901327 A MYPI9901327 A MY PI9901327A MY 121054 A MY121054 A MY 121054A
- Authority
- MY
- Malaysia
- Prior art keywords
- animal
- receptor antagonists
- calcilytic
- present
- calcium receptor
- Prior art date
Links
- 230000001126 calcilytic effect Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940123613 Calcium receptor antagonist Drugs 0.000 title abstract 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004079 mineral homeostasis Effects 0.000 abstract 1
- 230000000849 parathyroid Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8109398P | 1998-04-08 | 1998-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY121054A true MY121054A (en) | 2005-12-30 |
Family
ID=22162059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99001327A MY121054A (en) | 1998-04-08 | 1999-04-06 | Calcilytic compounds as calcium receptor antagonists. |
Country Status (33)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5180628A1 (es) * | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
| AR030684A1 (es) * | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| EP1308436B1 (en) | 2000-08-11 | 2008-10-15 | Japan Tobacco Inc. | Calcium receptor antagonists |
| WO2002034204A2 (en) * | 2000-10-25 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds |
| TWI316511B (en) * | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
| KR100696927B1 (ko) | 2003-04-23 | 2007-03-20 | 니뽄 다바코 산교 가부시키가이샤 | ＣａＳＲ 길항제 |
| EP1630157A4 (en) | 2003-05-28 | 2007-05-23 | Japan Tobacco Inc | ANTAGONIST OF CASR |
| US7265145B2 (en) | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
| US20070155819A1 (en) * | 2004-02-06 | 2007-07-05 | Marquis Robert W Jr | Calcilytic compounds |
| US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US7531518B2 (en) | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
| ES2400693T3 (es) | 2005-09-02 | 2013-04-11 | Amgen Inc. | Regulación del equilibrio de fluido intestinal usando calcimiméticos |
| US8093299B2 (en) * | 2007-03-30 | 2012-01-10 | Amgen Inc. | Methods of treating bowel disorders |
| BRPI0922503A2 (pt) | 2008-12-24 | 2018-11-06 | Daiichi Sankyo Company, Limited | composto, composição farmacêutica, métodos para melhorar o metabolismo ósseo, e para previnir ou tratar osteoporose |
| WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) * | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| DE3301198A1 (de) * | 1983-01-15 | 1984-07-19 | Hoechst Ag, 6230 Frankfurt | N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| CZ82198A3 (cs) * | 1995-09-21 | 1998-07-15 | Eli Lilly And Company | Selektivní ß3 adrenergičtí agonisté |
| WO1997037967A1 (en) | 1996-04-09 | 1997-10-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
-
1999
- 1999-04-06 AR ARP990101554A patent/AR018177A1/es unknown
- 1999-04-06 PE PE1999000275A patent/PE20000415A1/es not_active Application Discontinuation
- 1999-04-06 MY MYPI99001327A patent/MY121054A/en unknown
- 1999-04-07 EG EG36999A patent/EG24178A/xx active
- 1999-04-07 DZ DZ990052A patent/DZ2751A1/xx active
- 1999-04-08 MX MXPA00009844A patent/MXPA00009844A/es unknown
- 1999-04-08 IL IL13891899A patent/IL138918A0/xx unknown
- 1999-04-08 CO CO99020604A patent/CO5031246A1/es unknown
- 1999-04-08 CN CN99807083A patent/CN1304401A/zh active Pending
- 1999-04-08 DE DE69927008T patent/DE69927008T2/de not_active Expired - Lifetime
- 1999-04-08 CA CA002327279A patent/CA2327279A1/en not_active Abandoned
- 1999-04-08 SK SK1485-2000A patent/SK14852000A3/sk unknown
- 1999-04-08 PL PL99343357A patent/PL343357A1/xx not_active Application Discontinuation
- 1999-04-08 AU AU34819/99A patent/AU752389B2/en not_active Ceased
- 1999-04-08 KR KR1020007011166A patent/KR20010042526A/ko not_active Ceased
- 1999-04-08 US US09/647,793 patent/US6395919B1/en not_active Expired - Lifetime
- 1999-04-08 AP APAP/P/2000/001931A patent/AP1271A/en active
- 1999-04-08 AT AT99916516T patent/ATE303358T1/de not_active IP Right Cessation
- 1999-04-08 JP JP2000542291A patent/JP2002510671A/ja not_active Withdrawn
- 1999-04-08 HU HU0101346A patent/HUP0101346A3/hu unknown
- 1999-04-08 ES ES99916516T patent/ES2247795T3/es not_active Expired - Lifetime
- 1999-04-08 NZ NZ507288A patent/NZ507288A/en not_active IP Right Cessation
- 1999-04-08 WO PCT/US1999/007722 patent/WO1999051569A1/en not_active Ceased
- 1999-04-08 TR TR2000/02896T patent/TR200002896T2/xx unknown
- 1999-04-08 ID IDW20002001A patent/ID27004A/id unknown
- 1999-04-08 EA EA200001039A patent/EA200001039A1/ru unknown
- 1999-04-08 ZA ZA200005369A patent/ZA200005369B/xx unknown
- 1999-04-08 BR BR9909486-0A patent/BR9909486A/pt not_active Application Discontinuation
- 1999-04-08 EP EP99916516A patent/EP1070048B1/en not_active Expired - Lifetime
- 1999-08-04 UA UA2000105670A patent/UA58586C2/uk unknown
-
2000
- 2000-10-04 NO NO20005006A patent/NO20005006L/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000277A patent/OA11499A/en unknown
- 2000-11-07 BG BG104916A patent/BG104916A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY121054A (en) | Calcilytic compounds as calcium receptor antagonists. | |
| ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
| AP1869A (en) | b2- Adrenergic receptor agonists. | |
| BG106142A (en) | Glucocorticoid receptor modulators | |
| MY117251A (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
| UA74419C2 (uk) | Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату | |
| YU7797A (sh) | Kombinovana terapija za osteoporozu | |
| MXPA04006280A (es) | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. | |
| BR9711805A (pt) | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos | |
| LT2001004A (en) | Fertilizer from sapropel and manufacture thereof | |
| BG104315A (en) | Prostaglandine agonists and their application for the treatment of osteal diseases | |
| MXPA05002442A (es) | Imidazolopiridinas y metodos para la elaboracion y uso de las mismas. | |
| BR9910180A (pt) | Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
| BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
| BR0211932A (pt) | Métodos e composições para administração oral de hormÈnio de paratireóide, pth | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| DE60108094D1 (de) | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien | |
| TR200103638T2 (tr) | IL-8 Reseptör antagonistleri | |
| CA2296560A1 (en) | Amino acid derivatives useful to treat stroke | |
| BR9814867A (pt) | Método para tratar discinesias relacionadas a doenças ou induzidas por drogas | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
| WO2001055176A3 (en) | Methods for inhibiting smooth muscle cell proliferation | |
| WO2001032197A3 (en) | Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |